Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C–mutant non-small cell lung cancer
Open Access
- 2 July 2026
- journal article
- Published by Springer Nature in Oncogene
- Vol. 45 (31) , 3244-3257
Abstract
Kirsten rat sarcoma viral oncogene (KRAS) G12C inhibitors have demonstrated clinical efficacy against KRAS G12C-mutant non-small cell lung cancer (NSCLC); however, intrinsic and acquired resistance limit their therapeutic potential. Therefore, combination strategies are needed to address these limitations. While various combination regimens are currently being tested in clinical trials, treatments tailored to specific biomarkers remain underexplored. In this study, intrinsic and acquired KRAS G12C inhibitor-resistant tumor cells were established using patient-derived xenograft (PDX) and mouse models. We identified that tumor cell-autocrine amphiregulin (AREG)-mediated epidermal growth factor receptor (EGFR) phosphorylation plays a pivotal role in both intrinsic and acquired resistance to KRAS inhibitors. Notably, the same resistance mechanism was observed in central nervous system metastatic recurrence in a leptomeningeal carcinomatosis mouse model. RNAscope in situ hybridization detected AREG mRNA in tumor tissues and may serve as a diagnostic tool for assessing AREG expression. Furthermore, combining KRAS inhibitors with EGFR tyrosine kinase inhibitors suppressed tumor growth, effectively overcoming resistance. Notably, high AREG mRNA expression was observed in three of nine tumor samples from patients harboring the KRAS G12C mutation, including two patients who exhibited a poor response to sotorasib and one patient who achieved a partial response. In conclusion, AREG-mediated EGFR activation is a key driver of resistance to KRAS inhibitors in patients with KRAS G12C-mutant NSCLC. Combining EGFR and KRAS inhibition represents a promising strategy to overcome therapeutic resistance and may enhance and prolong clinical benefit in patients.Keywords
Funding Information
- Japan Society for the Promotion of Science (26K11115)
- Japan Society for the Promotion of Science (23K06648)
- Japan Society for the Promotion of Science (19H03665)
- Japan Society for the Promotion of Science (23K27609)
- Japan Lung Cancer Society
- Japan Science and Technology Agency (JPMJSP2135)
This publication has 50 references indexed in Scilit:
- K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactionsNature, 2013
- Automated Quantitative RNA in Situ Hybridization for Resolution of Equivocal and Heterogeneous ERBB2 (HER2) Status in Invasive Breast CarcinomaThe Journal of Molecular Diagnostics, 2013
- Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant CancersClinical Cancer Research, 2012
- Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast CancerCell, 2012
- The multiple roles of amphiregulin in human cancerBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2011
- A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell SurvivalCancer Cell, 2009
- Altered EGFR localization and degradation in human breast cancer cells with an amphiregulin/EGFR autocrine loopCellular Signalling, 2009
- Essential Role of c-Cbl in Amphiregulin-Induced Recycling and Signaling of the Endogenous Epidermal Growth Factor ReceptorBiochemistry, 2009
- Amphiregulin: A new growth factor in hepatocarcinogenesisCancer Letters, 2007
- Amphiregulin: a bifunctional growth-modulating glycoprotein produced by the phorbol 12-myristate 13-acetate-treated human breast adenocarcinoma cell line MCF-7.Proceedings of the National Academy of Sciences, 1988